Hebei Puzhou Pharmaceutical

Hebei Puzhou Pharmaceutical is an emerging Chinese pharmaceutical company founded in 2021 and headquartered in Shijiazhuang, Hebei Province. Operating under China's Marketing Authorization Holder (MAH) system, the company leverages an in-house Contract Research Organization (CRO) framework to drive drug R&D while outsourcing large-scale production to strategic manufacturing partners. Its development pipeline focuses on clinically advantageous modified new drugs and high-end generic small molecules across cardiovascular, gastrointestinal, and other therapeutic areas. The company's lead product, Levamlodipine Besylate Tablets for hypertension, received NMPA approval in 2024, while its Rabeprazole Sodium Enteric-coated Tablets for gastrointestinal disorders are currently under regulatory review for marketing authorization.